Rituximab for treatment-refractory pemphigus and pemphigoid: A case series of 17 patients
- 1 September 2011
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 65 (3) , 552-558
Abstract
No abstract availableKeywords
Funding Information
- Schleswig-Holstein Cluster of Excellence in Inflammation Research (DFG EXC 306/1)
This publication has 14 references indexed in Scilit:
- Rituximab in Severe PemphigusAnnals of the New York Academy of Sciences, 2009
- B-Cell-Directed Therapy for Inflammatory Skin DiseasesJournal of Investigative Dermatology, 2009
- A review of the current use of rituximab in autoimmune diseasesInternational Immunopharmacology, 2009
- CD20-directed therapy in autoimmune diseases involving the skin: role of rituximabExpert Review of Dermatology, 2008
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007
- Treatment of Severe Pemphigus With RituximabArchives of Dermatology, 2007
- Rituximab in autoimmune bullous diseases: mixed responses and adverse effectsBritish Journal of Dermatology, 2007
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinNew England Journal of Medicine, 2006
- Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoidJournal of the American Academy of Dermatology, 2004